WEBULL
News
ADOCY
11.80
NaN%
--
Weekly Report: what happened at ADOCY last week (0908-0912)?
Weekly Report · 09/15 11:29
Weekly Report: what happened at ADOCY last week (0901-0905)?
Weekly Report · 09/08 11:32
Weekly Report: what happened at ADOCY last week (0825-0829)?
Weekly Report · 09/01 11:26
Weekly Report: what happened at ADOCY last week (0818-0822)?
Weekly Report · 08/25 11:39
Weekly Report: what happened at ADOCY last week (0811-0815)?
Weekly Report · 08/18 11:29
Weekly Report: what happened at ADOCY last week (0804-0808)?
Weekly Report · 08/11 11:38
Weekly Report: what happened at ADOCY last week (0728-0801)?
Weekly Report · 08/04 11:40
Weekly Report: what happened at ADOCY last week (0721-0725)?
Weekly Report · 07/28 11:41
Weekly Report: what happened at ADOCY last week (0714-0718)?
Weekly Report · 07/21 11:30
Weekly Report: what happened at ADOCY last week (0707-0711)?
Weekly Report · 07/14 11:41
Weekly Report: what happened at ADOCY last week (0630-0704)?
Weekly Report · 07/07 11:31
Weekly Report: what happened at ADOCY last week (0623-0627)?
Weekly Report · 06/30 11:38
Weekly Report: what happened at ADOCY last week (0616-0620)?
Weekly Report · 06/23 11:30
Weekly Report: what happened at ADOCY last week (0609-0613)?
Weekly Report · 06/16 11:38
Weekly Report: what happened at ADOCY last week (0602-0606)?
Weekly Report · 06/09 11:39
Weekly Report: what happened at ADOCY last week (0526-0530)?
Weekly Report · 06/02 11:49
Weekly Report: what happened at ADOCY last week (0519-0523)?
Weekly Report · 05/26 11:48
Weekly Report: what happened at ADOCY last week (0512-0516)?
Weekly Report · 05/19 11:37
Weekly Report: what happened at ADOCY last week (0505-0509)?
Weekly Report · 05/12 11:38
Weekly Report: what happened at ADOCY last week (0428-0502)?
Weekly Report · 05/05 11:40
More
Webull provides a variety of real-time ADOCY stock news. You can receive the latest news about Adocia through multiple platforms. This information may help you make smarter investment decisions.
About ADOCY
Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.